Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–115 of 115 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HIV-Infected Children Clear all

Conditions: Sleep, HIV Infections
Interventions: Wrist Actigraphy; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 8 Years to 17 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections, Chickenpox
Interventions: Varicella Virus Vaccine (Live); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 22
States / cities: Long Beach, California • Los Angeles, California • Torrance, California + 13 more

Conditions: HIV Infections, Hepatitis B, Measles, Pneumococcal Infections, Pertussis
Interventions: Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Measles-Mumps-Rubella Vaccine (Live), Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Hepatitis B Vaccine (Recombinant); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 18 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 38
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 26 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Months to 13 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 4
States / cities: Los Angeles, California • Oakland, California • Houston, Texas

Conditions: HIV Infections
Interventions: CD4 Antigens; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: San Francisco, California • Stanford, California • Chicago, Illinois + 2 more

Conditions: Human Immunodeficiency Virus (HIV)
Interventions: DRV/COBI FDC; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 3 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions: ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 4 Weeks to 17 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 7
States / cities: Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more

Conditions: HIV Infections
Interventions: Dose adjustment of Kaletra; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 4 Years to 21 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: HIV Infections
Interventions: Amprenavir; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 6 Months to 18 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Fort Lauderdale, Florida • Memphis, Tennessee

Conditions: HIV Infections
Interventions: HAART; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions: E/C/F/TAF, E/C/F/TAF (Low Dose); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 5
States / cities: Long Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more

Conditions: HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 17 Years
Enrollment: 819 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 76
States / cities: Birmingham, Alabama • Downey, California • La Jolla, California + 46 more

Conditions: HIV Infections
Interventions: Lopinavir/ritonavir, Saquinavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 13
States / cities: Birmingham, Alabama • Long Beach, California • San Francisco, California + 9 more

Conditions: HIV Infections
Interventions: Abacavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 13 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 7
States / cities: Los Angeles, California • San Diego, California • New Orleans, Louisiana + 4 more

Conditions: Vitamin D Deficiency
Interventions: Not listed
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 8 Years to 25 Years
Enrollment: 290 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Atlanta, Georgia • Cleveland, Ohio

Conditions: HIV Infections With Multi Drug Resistant Virus
Interventions: Fostemsavir; Drug
Lead sponsor: PENTA Foundation; Network
Eligibility: 6 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV
Interventions: Teaching, Raising, and Communicating with Kids (TRACK), Treatment as usual; Behavioral · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 6 Years to 65 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections
Interventions: Antiretroviral therapy; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 7 Years to 18 Years
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 2
States / cities: Houston, Texas • Salt Lake City, Utah

Conditions: Encephalopathies, HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 12 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Jacksonville, Florida • Baltimore, Maryland + 3 more

Search by objective public record fields.

Sleep, HIV Disease Progression, and Function in HIV Infected Children and Adolescents

Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox

Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

A Study of Two Forms of Pentamidine in HIV-Infected Children Who May Have Pneumocystis Carinii Pneumonia

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection

A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

Optimizing Antiretroviral Therapy in HIV-Infected Children and Adolescents

Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors

Therapeutic Drug Monitoring and Viral Resistance Testing in the Treatment of HIV-Infected Children

Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children

Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV

The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children

Vitamin D and HIV-Cardiovascular Disease in Children and Young Adults

Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance

Assisting HIV-infected Mothers in Disclosing Their Serostatus to Their Children

The Metabolic Effects of Protease Inhibitors in HIV Infected Children

A Study of Azidothymidine in HIV-Infected Children